Cilotti A, Iacconi C, Marini C, Moretti M, Mazzotta D, Traino C, Naccarato A G, Piagneri V, Giaconi C, Bevilacqua G, Bartolozzi C
Division of Diagnostic and Interventional Radiology, University of Pisa, and Azienda Ospedaliera Universitaria Pisana, Pisa, Italy.
Radiol Med. 2007 Mar;112(2):272-86. doi: 10.1007/s11547-007-0141-9. Epub 2007 Mar 19.
The aim of this study was to evaluate the role of magnetic resonance imaging (MRI) in patients with microcalcifications classed as Breast Imaging Reporting and Data Systems (BI-RADS) 3-5.
Fifty-five patients with mammographic microcalcifications classified as BI-RADS categories 3, 4 or 5 underwent MRI and biopsy with stereotactic vacuum-assisted biopsy (VAB). Our gold standard was microhistology in all cases and histology with histological grading in patients who underwent surgery. Patients with a microhistological diagnosis of benign lesions underwent mammographic follow-up for at least 12 months. MRI was performed with a 1.5-Tesla (T) unit, and T1 coronal three-dimensional (3D) fast low-angle shot sequences were acquired before and after injection of paramagnetic contrast agent (0.1 mmol/kg). MRI findings, according to the Fisher score, were classified into BI-RADS classes. In patients with cancer who underwent surgery, we retrospectively compared the extension of the mammographic and MRI findings with histological extension.
Histology revealed 26 ductal in situ cancers (DCIS) and ductal microinvasive cancers (DCmic), three atypical ductal hyperplasias (ADH) and 26 benign conditions. Histological grading of the 26 patients with cancer revealed four cases of G1, 11 cases of G2 and 11 cases of G3. If we consider mammographic BI-RADS category 3 as benign and BI-RADS 4 and 5 as malignant, mammography had 77% sensitivity, 59% specificity, 63% positive predictive value (PPV), 74% negative predictive value (NPV) and 67.2% diagnostic accuracy. If we consider MRI BI-RADS categories 1, 2 and 3 as benign and 4 and 5 as malignant, MRI had 73% sensitivity, 76% specificity, 73% PPV, 76% NPV and 74.5% diagnostic accuracy. As regards disease extension, mammography had 45% sensitivity and MRI had 84.6% sensitivity.
Mammography and stereotactic biopsy still remain the only techniques for characterising microcalcifications. MRI cannot be considered a diagnostic tool for evaluating microcalcifications. It is, however, useful for identifying DCIS with more aggressive histological grades. An important application of MRI in patients with DCIS associated with suspicious microcalcifications could be to evaluate disease extension after a microhistological diagnosis of malignancy, as it allows a more accurate presurgical planning.
本研究旨在评估磁共振成像(MRI)在乳腺影像报告和数据系统(BI-RADS)分类为3-5类的微钙化患者中的作用。
55例乳腺钼靶微钙化分类为BI-RADS 3、4或5类的患者接受了MRI检查,并采用立体定位真空辅助活检(VAB)进行活检。我们的金标准是所有病例的微观组织学检查,以及接受手术患者的组织学检查和组织学分级。微观组织学诊断为良性病变的患者接受了至少12个月的乳腺钼靶随访。使用1.5特斯拉(T)设备进行MRI检查,在注射顺磁性造影剂(0.1 mmol/kg)前后采集T1冠状三维(3D)快速低角度激发序列。根据Fisher评分将MRI结果分类为BI-RADS类别。在接受手术的癌症患者中,我们回顾性比较了乳腺钼靶和MRI结果的范围与组织学范围。
组织学检查发现26例导管原位癌(DCIS)和导管微浸润癌(DCmic)、3例非典型导管增生(ADH)和26例良性病变。26例癌症患者的组织学分级显示,G1级4例,G2级11例,G3级11例。如果将乳腺钼靶BI-RADS 3类视为良性,4类和5类视为恶性,乳腺钼靶的敏感性为77%,特异性为59%,阳性预测值(PPV)为63%,阴性预测值(NPV)为74%,诊断准确性为67.2%。如果将MRI BI-RADS 1、2和3类视为良性,4类和5类视为恶性,MRI的敏感性为73%,特异性为76%,PPV为73%,NPV为76%,诊断准确性为74.5%。关于疾病范围,乳腺钼靶的敏感性为45%,MRI的敏感性为84.6%。
乳腺钼靶和立体定位活检仍然是表征微钙化的唯一技术。MRI不能被视为评估微钙化的诊断工具。然而,它有助于识别具有更侵袭性组织学分级的DCIS。MRI在伴有可疑微钙化的DCIS患者中的一个重要应用可能是在微观组织学诊断为恶性肿瘤后评估疾病范围,因为它可以实现更准确的术前规划。